TY  - JOUR
AU  - Richter, Günther H S
AU  - Ranft, Andreas
AU  - Kerkhoff, Maximilian
AU  - Jens, Marvin
AU  - Kirchberg, Ina E
AU  - Dirksen, Uta
TI  - The Puzzle of Genetic Stability and Chromosomal Copy Number Alterations for the Therapy of Ewing Sarcoma.
JO  - Cancers
VL  - 17
IS  - 22
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2025-02646
SP  - 3719
PY  - 2025
AB  - Studies of the genomic stability of Ewing sarcoma (EwS) have produced contradictory findings. While they are generally characterized by low mutation rates of individual genes, several cases exhibit genomic alterations that manifest as chromosomal gains and losses. Taken together, these alterations represent independent biomarkers for EwS, such as loss of heterozygosity (LOH) or an altered genome. Patients with primary EwS tumors with fewer than three copy number alterations (CNAs) have a better prognosis than those with more CNAs. The functional mechanisms underlying this chromosomal instability are not yet clear. However, there are indications that this may be directly caused by the EWSR1::ETS translocations that are characteristic of EwS. The transcriptional behavior of the chimeric transcription factor EWSR1-FLI1 leads to the formation of R-loop DNA-RNA hybrids that form when RNA binds back to DNA during transcription and increased replication stress, which may result in structural chromosomal changes. Additionally, the formation of EWSR1 fusion genes in EwS results in the loss of one or both wild-type EWSR1 alleles in sarcoma cells. As chromosome segregation has been observed under loss of wild-type EWSR1, EWSR1 loss has been proposed as a potential source of LOH. So, it is highly probable that a chromosomal translocation and the subsequent formation of the EWSR1-ETS fusion protein cause the genomic alterations in EwS. This indicates that targeted therapy should be directed against the CNA and LOH biology caused by the fusion protein.
KW  - EWSR1 haploinsufficiency (Other)
KW  - Ewing sarcoma (Other)
KW  - biomarker (Other)
KW  - loss of heterozygosity (Other)
KW  - replication stress (Other)
KW  - replication stress directed therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41301081
DO  - DOI:10.3390/cancers17223719
UR  - https://inrepo02.dkfz.de/record/306609
ER  -